West Pharmaceutical(US:WST) Prnewswireยท2025-06-06 13:41Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [4]. - Specific issues highlighted include the operational inefficiencies of the SmartDose device, which was expected to be a high-margin growth product but instead diluted profit margins [4]. - The allegations also mention the risk of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers, due to these margin pressures [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [5]. - Following this announcement, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on the same day [5]. Group 3: Legal Proceedings - Investors who purchased securities in West between February 16, 2023, and February 12, 2025, are encouraged to discuss their legal rights and options, with a deadline of July 7, 2025, to seek the role of lead plaintiff in the federal securities class action [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [6].